Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0
|
作者：
Dimitrios Pectasides
Vasilios Karavasilis
George Papaxoinis
Georgia Gourgioti
Thomas Makatsoris
Georgia Raptou
Eleni Vrettou
Joseph Sgouros
Epaminontas Samantas
George Basdanis
Pavlos Papakostas
Dimitrios Bafaloukos
Vassiliki Kotoula
Haralambos P. Kalofonos
Chrisoula D. Scopa
George Pentheroudakis
George Fountzilas
机构：
[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine
[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital
[3] Section of Biostatistics,Division of Oncology, Department of Medicine
[4] Hellenic Cooperative Oncology Group,Department of Pathology
[5] Data Office,Third Department of Medical Oncology
[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital
[7] University of Patras Medical School,Department of Medical Oncology
[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research
[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[11] “Hippokration” Hospital,Department of Medical Oncology
[12] “Metropolitan” Hospital,undefined
[13] Aristotle University of Thessaloniki School of Medicine,undefined
[14] University Hospital,undefined
[15] University of Patras Medical School,undefined
[16] Ioannina University Hospital,undefined
来源：
BMC Cancer | / 15卷
关键词：
Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
    Katsuki Danno
    Taishi Hata
    Koki Tamai
    Yujiro Fujie
    Yoshihito Ide
    Ho Min Kim
    Tadashi Ohnishi
    Shunji Morita
    Shinichi Yoshioka
    Toshihiro Kudo
    Junichi Nishimura
    Chu Matsuda
    Hiroki Akamatsu
    Tsunekazu Mizushima
    Riichiro Nezu
    Yuichiro Doki
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 777 - 785
  • [32] High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
    Yang, I-Ping
    Miao, Zhi-Feng
    Huang, Ching-Wen
    Tsai, Hsiang-Lin
    Yeh, Yung-Sung
    Su, Wei-Chih
    Chang, Tsung-Kun
    Chang, Se-fen
    Wang, Jaw-Yuan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [33] Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer
    Moretto, Roberto
    Falcone, Alfredo
    Cremolini, Chiara
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (09) : 2652 - 2654
  • [34] A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC).
    Fakih, M. G.
    Pendyala, L.
    Toth, K.
    Creaven, P.
    Soehnlein, N.
    Litwin, A.
    Trump, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 168S - 168S
  • [35] Phase III trial of capecitabine plus oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC)
    Rothenberg, M. L.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J. V.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer:: A planned safety analysis in 1,864 patients
    Schmoll, Hans-Joachim
    Cartwright, Thomas
    Tabernero, Josep
    Nowacki, Marek P.
    Figer, Arie
    Maroun, Jean
    Price, Timothy
    Lim, Robert
    Van Cutsem, Eric
    Park, Young-Suk
    McKendrick, Joseph
    Topham, Claire
    Soler-Gonzalez, Gemma
    de Braud, Filipo
    Hill, Mark
    Sirzen, Florin
    Haller, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) : 102 - 109
  • [37] Oxaliplatin, 5-fluorouracil (FU) & folinic acid (FA) first-line combination therapy in colorectal cancer:: Results of a phase III trial.
    Seymour, MT
    Cassidy, J
    Wilson, C
    Papamichael, D
    Homerin, M
    Figer, A
    de Gramont, A
    BRITISH JOURNAL OF CANCER, 1998, 78 : 21 - 21
  • [38] Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer
    Hamaya, Yasushi
    Guarinos, Carla
    Tseng-Rogenski, Stephanie S.
    Iwaizumi, Moriya
    Das, Ritabrata
    Jover, Rodrigo
    Castells, Antoni
    Llor, Xavier
    Andreu, Montserrat
    Carethers, John M.
    PLOS ONE, 2015, 10 (05):
  • [39] A multi-institutional randomized phase II study on the timing of oxaliplatin plus 5-fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR study
    Kavan, P.
    Barrera, I.
    Azoulay, L.
    Martin, A-G.
    Vasilevsky, C.
    Boutros, M.
    Ferland, E.
    Batist, G.
    Vuong, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
    Rothenberg, M. L.
    Cox, J. V.
    Butts, C.
    Navarro, M.
    Bang, Y. -J.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Laguerre, S.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1720 - 1726
12345